Rice Hall James & Associates, LLC holds a diversified book of 243 stocks worth $1.8B as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Upwork Inc and trimmed Fabrinet. Their largest long position is Ligand Pharmaceuticals at 3% of the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1230765/holdings"
Use Arkolith to show RICE HALL JAMES & ASSOCIATES, LLC's latest holdings, largest changes, and filing provenance.
Top-heavy: diversified book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
96% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Ligand Pharmaceuticals Inc COM NEW | $56.6M | 283.6K | 3.2% | ▲+1.4% Added · +4K sh | |
| 2 | Fabrinet SHS | $55.2M | 105.8K | 3.1% | ▼−0.7% Reduced · −701 sh | |
| 3 | Arlo Technologies Inc COM | $52.1M | 3.66M | 2.9% | ▲+2.3% Added · +83K sh | |
| 4 | Xpo Inc COM | $43.6M | 224.3K | 2.4% | ▲+2.3% Added · +5K sh | |
| 5 | Aci Worldwide Inc COM | $41.1M | 1.00M | 2.3% | ▲+2.2% Added · +22K sh | |
| 6 | Stride Inc COM | $38.7M | 438.4K | 2.2% | ▲+2.5% Added · +11K sh | |
| 7 | Shift4 PMTS Inc CL A | $37.1M | 847.7K | 2.1% | ▲+28% Added · +184K sh | |
| 8 | Donnelley Finl Solutions Inc COM | $36.8M | 780.0K | 2.0% | ▲+1.8% Added · +14K sh | |
| 9 | Ascendis Pharma A/s SPONSORED ADR | $33.9M | 148.4K | 1.9% | ▲+2.3% Added · +3K sh | |
| 10 | Ziff Davis Inc COM | $33.6M | 799.8K | 1.9% | ▲+7.5% Added · +56K sh | |
| 11 | Establishment Labs Hldgs Inc COM | $31.2M | 548.7K | 1.7% | ▼−16% Reduced · −103K sh | |
| 12 | Prestige Consmr Healthcare I COM | $30.9M | 521.6K | 1.7% | ▲+4.2% Added · +21K sh | |
| 13 | Kiniksa Pharmaceuticals Intl ORD SHS CL A | $29.3M | 608.4K | 1.6% | ▲+2.0% Added · +12K sh | |
| 14 | Armstrong World Inds Inc New COM | $29.1M | 176.9K | 1.6% | ▲+2.2% Added · +4K sh | |
| 15 | Clear Secure Inc COM CL A | $27.9M | 577.1K | 1.6% | ▼−37% Reduced · −337K sh | |
| 16 | Wex Inc COM | $27.6M | 180.3K | 1.5% | ▲+3.5% Added · +6K sh | |
| 17 | Wix Com Ltd SHS | $26.7M | 296.8K | 1.5% | ▲+19% Added · +47K sh | |
| 18 | Sportradar Group AG CLASS A ORD SHS | $26.5M | 1.58M | 1.5% | ▲+39% Added · +442K sh | |
| 19 | Godaddy Inc CL A | $26.4M | 319.5K | 1.5% | ▲13× Added · +295K sh | |
| 20 | Genpact Limited SHS | $26.2M | 704.1K | 1.5% | ▲+173% Added · +446K sh | |
| 21 | Ituran Location And Control SHS | $26.1M | 531.9K | 1.5% | ▲+0.7% Added · +4K sh | |
| 22 | Medpace Hldgs Inc COM | $25.9M | 54.0K | 1.4% | ▼−14% Reduced · −9K sh | |
| 23 | Supernus Pharmaceuticals COM | $24.7M | 477.4K | 1.4% | ▲+2.0% Added · +10K sh | |
| 24 | Ingevity Corp COM | $24.6M | 345.1K | 1.4% | ▲+2.3% Added · +8K sh | |
| 25 | Biocryst Pharmaceuticals Inc COM | $21.2M | 2.23M | 1.2% | ▲+17% Added · +326K sh | |
| 26 | Birkenstock Holding PLC COM SHS | $21.2M | 590.4K | 1.2% | ▲+27% Added · +124K sh | |
| 27 | Lemaitre Vascular Inc COM | $20.2M | 184.7K | 1.1% | ▲+1.3% Added · +2K sh | |
| 28 | LKQ Corp COM | $20.1M | 685.2K | 1.1% | ▲+5.1% Added · +33K sh | |
| 29 | Liquidity Svcs Inc COM | $18.3M | 597.2K | 1.0% | ▲+1.9% Added · +11K sh | |
| 30 | Radware Ltd ORD | $18.0M | 683.3K | 1.0% | ▲+2.4% Added · +16K sh | |
| 31 | Viridian Therapeutics Inc COM | $17.6M | 898.6K | 1.0% | ▲+1.6% Added · +14K sh | |
| 32 | Federal Agric MTG Corp CL C | $17.0M | 114.7K | 0.9% | ▲+2.0% Added · +2K sh | |
| 33 | Quidelortho Corp COM | $16.9M | 1.03M | 0.9% | ▲+23% Added · +193K sh | |
| 34 | Euronet Worldwide Inc COM | $16.1M | 242.0K | 0.9% | ▲+8.3% Added · +19K sh | |
| 35 | Amdocs Ltd SHS | $15.5M | 238.1K | 0.9% | ▲+3.5% Added · +8K sh | |
| 36 | Chart Inds Inc COM | $15.0M | 72.7K | 0.8% | ▼−43% Reduced · −56K sh | |
| 37 | Vail Resorts Inc COM | $15.0M | 116.8K | 0.8% | ▲+5.9% Added · +7K sh | |
| 38 | Upwork Inc COM | $14.3M | 1.31M | 0.8% | ▲New New position | |
| 39 | Maximus Inc COM | $14.3M | 222.9K | 0.8% | ▲+4.2% Added · +9K sh | |
| 40 | Nexxen Intl Ltd SHS NEW | $13.8M | 2.12M | 0.8% | ▲+7.6% Added · +149K sh | |
| 41 | Alkermes PLC SHS | $13.8M | 390.3K | 0.8% | ▲+2.9% Added · +11K sh | |
| 42 | Acadia Pharmaceuticals Inc COM | $13.7M | 617.5K | 0.8% | ▲+2.3% Added · +14K sh | |
| 43 | Mirum Pharmaceuticals Inc COM | $13.6M | 147.0K | 0.8% | ▼−11% Reduced · −17K sh | |
| 44 | Varex Imaging Corp COM | $13.5M | 1.27M | 0.8% | ▲+18% Added · +192K sh | |
| 45 | Neurocrine Biosciences Inc COM | $13.2M | 100.0K | 0.7% | ▲+2.0% Added · +2K sh | |
| 46 | Harrow Inc COM | $13.0M | 368.2K | 0.7% | ▲+1.7% Added · +6K sh | |
| 47 | Lci Inds COM | $13.0M | 105.3K | 0.7% | ▲+2.7% Added · +3K sh | |
| 48 | Cra Intl Inc COM | $12.2M | 75.4K | 0.7% | ▲+1.5% Added · +1K sh | |
| 49 | Shutterstock Inc COM | $12.2M | 733.7K | 0.7% | ▲+7.3% Added · +50K sh | |
| 50 | Bank Ozk Little Rock Ark COM | $11.9M | 259.6K | 0.7% | ▲+1.9% Added · +5K sh |
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 15, 2026 | 243 | $1.8B | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 17, 2026 | 243 | $1.8B | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Oct 16, 2025 | 248 | $1.8B | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 11, 2025 | 247 | $1.9B | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 1, 2025 | 248 | $1.7B | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Jan 31, 2025 | 249 | $1.8B | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Oct 28, 2024 | 250 | $1.8B | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 7, 2024 | 256 | $1.7B | 13F-HR |
| Q1 2024 | Mar 31, 2024 | Apr 23, 2024 | 257 | $1.8B | 13F-HR |
| Q4 2023 | Dec 31, 2023 | Feb 9, 2024 | 260 | $1.7B | 13F-HR |
| Q3 2023 | Sep 30, 2023 | Nov 2, 2023 | 260 | $1.6B | 13F-HR |
| Q2 2023 | Jun 30, 2023 | Jul 24, 2023 | 262 | $1.8B | 13F-HR |
| Q1 2023 | Mar 31, 2023 | May 12, 2023 | 262 | $1.8B | 13F-HR |
| Q4 2022 | Dec 31, 2022 | Jan 27, 2023 | 260 | $1.7B | 13F-HR |
| Q3 2022 | Sep 30, 2022 | Nov 1, 2022 | 265 | $1.7B | 13F-HR |
| Q2 2022 | Jun 30, 2022 | Aug 8, 2022 | 265 | $2.1B | 13F-HR |
| Q1 2022 | Mar 31, 2022 | May 26, 2022 | 306 | $2.5B | 13F-HR/A |
| Q4 2021 | Dec 31, 2021 | Feb 14, 2022 | 312 | $2.8B | 13F-HR |
| Q3 2021 | Sep 30, 2021 | Nov 9, 2021 | 309 | $2.7B | 13F-HR |
| Q2 2021 | Jun 30, 2021 | Jul 29, 2021 | 313 | $2.8B | 13F-HR |
| Q1 2021 | Mar 31, 2021 | May 14, 2021 | 315 | $3.1B | 13F-HR |
| Q4 2020 | Dec 31, 2020 | Feb 16, 2021 | 300 | $2.8B | 13F-HR |
| Q3 2020 | Sep 30, 2020 | Nov 16, 2020 | 273 | $2.5B | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.